Leukocytes Do Not Influence the Safety and Efficacy of Platelet-Rich Plasma Injections for the Treatment of Knee Osteoarthritis
Romandini I · The American Journal of Sports Medicine (2024)
DOI: 10.1177/03635465241283500This double-blind RCT compared leukocyte-rich PRP (LR-PRP) versus leukocyte-poor PRP (LP-PRP) directly for knee osteoarthritis. Unlike most studies that compare PRP to HA or placebo, this head-to-head comparison specifically tested whether leukocyte content influences outcomes. The study found no significant difference in efficacy or safety between the two formulations.
Clinical Relevance
Suggests that for knee OA specifically, the leukocyte-rich versus leukocyte-poor debate may be less important than platelet concentration. Clinicians should focus on adequate platelet dosing rather than obsessing over leukocyte content for this indication.
Key Takeaways
- No significant difference between LR-PRP and LP-PRP for knee OA
- Both formulations showed similar clinical improvement
- Adverse event profiles were comparable
- Challenges the assumption that leukocyte content is a critical differentiator for knee OA
- Directly addresses one of the most debated variables in PRP preparation
Key Findings
Leukocytes did not influence clinical efficacy or safety. Both LR-PRP and LP-PRP provided similar outcomes at 12 months.
Clinical Context
Study Design
Randomized Controlled Trial (Double-Blind)
Condition
Knee Osteoarthritis
Follow-up
12 months
Control Group
LR-PRP vs LP-PRP (head-to-head)
Primary Outcome
Clinical efficacy and adverse events
PRP Protocol & Intervention
Leukocyte Status
LR-PRP vs LP-PRP